Human amylin is produced primarily by pancreatic beta cells and released alongside insulin after food intake.

Cagrilintide retains the general amylin framework while replacing six residues to alter stability, solubility, receptor behaviour and aggregation tendency.

Its peptide chain is also attached to a long fatty-acid-derived moiety. This makes it a lipidated peptide rather than an unmodified short hormone.

Earlier development codes include AM833 and NN0174-0833. Novo Nordisk’s current phase-three pipeline also identifies its cagrilintide monotherapy programme as NN9833.

The molecule is being developed independently and as one component of CagriSema, which combines cagrilintide with the GLP-1 receptor agonist semaglutide.

Amylin is stored with insulin in secretory granules within pancreatic beta cells.

It is released after meals in response to nutrient exposure and rising blood glucose.

The hormone communicates with brain regions involved in satiation, meal termination, nausea, food reward and energy balance.

Important regions include the area postrema and nucleus of the solitary tract within the hindbrain, together with hypothalamic and reward-related neural networks.

Native amylin can slow gastric emptying, reduce post-meal glucagon secretion and help limit meal size.

In type 1 diabetes, beta-cell destruction produces deficiency of both insulin and amylin.

In type 2 diabetes, amylin production and action can become abnormal alongside beta-cell dysfunction and insulin resistance.

The cysteines at positions two and seven are connected through a disulphide bond.

The lysine at position one carries the lipidated linker on its side-chain amino group.

The sequence alone does not represent the complete medicine because it omits the covalently attached gamma-glutamyl and dicarboxylic-fatty-acid structure.

Proline residues restrict the peptide backbone and can interfere with the extended beta-sheet structures involved in amyloid formation.

Replacing multiple residues does not simply create a more stable copy of amylin. It creates a new pharmacological substance with its own receptor profile and safety requirements.

The first lysine carries a gamma-glutamyl linker connected to a 19-carboxynonadecanoyl group.

This is a long dicarboxylic fatty-acid-derived structure.

Fatty-acid attachment allows reversible non-covalent association with circulating albumin.

Albumin binding reduces immediate kidney filtration and can protect part of the molecule from rapid enzymatic degradation.

An early human trial reported a cagrilintide half-life of approximately 159 to 195 hours, which is compatible with prolonged experimental exposure.

The measured peak concentration occurred substantially later than it would for unmodified amylin.

Human amylin can form insoluble amyloid fibrils, particularly within the pancreatic islets of people with type 2 diabetes.

Native amylin is therefore unsuitable as a straightforward injectable medicine.

Proline substitutions disrupt regions that readily adopt fibril-forming beta-sheet structures.

Reduced intrinsic amyloid tendency does not eliminate every pharmaceutical aggregation risk.

Lipidated peptides can form dimers, oligomers, particles or surface-associated aggregates during synthesis, purification, freeze drying, storage and temperature excursions.

Aggregates can affect active concentration, absorption and immunogenicity.

The calcitonin receptor is a class-B G-protein-coupled receptor.

Association with receptor-activity-modifying protein one creates the AMY1 receptor.

Association with receptor-activity-modifying protein two creates the AMY2 receptor.

Association with receptor-activity-modifying protein three creates the AMY3 receptor.

The receptor’s pharmacology changes according to the associated modifying protein.

Cagrilintide has been described as a non-selective agonist at human amylin receptors and the uncomplexed calcitonin receptor.

This differentiates it from newer candidates being designed for stronger selectivity towards one amylin-receptor subtype.

Meal Termination

Amylin-receptor signalling in the hindbrain contributes to the perception that sufficient food has been consumed.

This can reduce meal size before physical stomach capacity is reached.

Appetite Between Meals

Signals from the area postrema and nucleus of the solitary tract communicate with hypothalamic networks that influence hunger and energy balance.

Food Reward

Amylin pathways also interact with neural systems involved in food motivation and reward.

Reduced reward-driven eating is not equivalent to elimination of emotional, social or environmental eating behaviour.

Energy Expenditure

Most clinical weight reduction appears to arise from lower energy intake.

No evidence establishes that cagrilintide produces substantial independent fat burning or overrides the biological adaptation to weight loss.

Native amylin and the approved analogue pramlintide slow gastric emptying and suppress inappropriate post-meal glucagon secretion.

These effects can reduce the rate at which glucose appears in the circulation after eating.

Cagrilintide’s prolonged receptor activity may not reproduce the exact time course of short-acting amylin.

The phase-three combination studies show improvements in glycated haemoglobin among participants with type 2 diabetes, but semaglutide is a major contributor to glucose-dependent insulin and glucagon effects.

Combination findings therefore cannot determine the independent glucose-lowering contribution of cagrilintide without direct monotherapy comparison.

Semaglutide, liraglutide and related medicines activate the GLP-1 receptor.

Cagrilintide activates amylin and calcitonin-family receptors.

Both systems can reduce appetite and food intake, but they do so through overlapping and partly distinct neural populations.

The combination strategy aims to engage complementary pathways rather than increase the action of one receptor alone.

Cagrilintide should therefore not be described as another form of semaglutide, Ozempic or Wegovy.

Cagrilintide appears in Peptides UK listings as a lyophilised vial, research standard, premixed blend or combination with semaglutide and other metabolic peptides.

Common descriptions promise appetite elimination, faster weight loss, reduced cravings, overcoming a GLP-1 plateau, improved fat loss and fewer adverse effects than established medicines.

These claims frequently omit that published clinical studies used Novo Nordisk’s defined investigational product under trial monitoring.

Cagrilintide is more structurally complex than many short research peptides because identity depends on a 37-residue sequence, disulphide pairing, amidation and a precisely attached lipid side chain.

A supplier producing only an unmodified peptide backbone would not be supplying the clinical-development molecule.

Grey-market combinations create additional uncertainty because each active component and its quantity must be established independently.

Early development used escalating exposure to determine whether the prolonged amylin analogue could be administered repeatedly.

Researchers monitored gastrointestinal symptoms, vital signs, laboratory measurements, antibodies and pharmacokinetic concentrations.

These studies established a prolonged half-life and supported further weekly-treatment research.

Early trials were not designed to determine long-term cardiovascular outcomes, rare adverse effects or durability over several years.

Small phase-one cohorts can miss events that occur infrequently or only in people with complex medical conditions.

The multicentre trial enrolled adults with obesity or overweight and at least one weight-related condition.

Participants were assigned to several weekly cagrilintide groups, placebo or daily liraglutide as an active comparator.

Treatment was combined with lifestyle intervention and included a dose-escalation period.

Weight reduction increased across the cagrilintide groups.

At the upper studied exposure, estimated mean weight reduction reached approximately 10.8% after 26 weeks, compared with approximately 3.0% for placebo.

Cagrilintide at the highest investigated exposure produced greater average weight loss than liraglutide within the study’s analysis.

Gastrointestinal symptoms were the most frequent treatment-related issue and were generally reported as mild to moderate.

REDEFINE 1 enrolled 3,417 adults with obesity or overweight and a weight-related condition who did not have diabetes.

Participants were allocated to CagriSema, semaglutide, cagrilintide or placebo alongside lifestyle intervention.

The cagrilintide monotherapy group contained 302 participants.

Under the trial-product estimand, which estimated the effect if participants adhered to treatment, cagrilintide produced 11.8% mean weight reduction at 68 weeks.

Placebo produced 2.3% mean reduction under the same analysis.

More than 30% of cagrilintide participants reached at least 15% weight reduction in Novo Nordisk’s reported subanalysis.

Gastrointestinal adverse events occurred in approximately 54% of cagrilintide participants and 40% of placebo participants.

Permanent discontinuation because of gastrointestinal adverse events occurred in approximately 1.3% of the cagrilintide group.

Cagrilintide supplies prolonged amylin and calcitonin-family receptor activity.

Semaglutide supplies prolonged GLP-1 receptor activity.

The combination aims to produce complementary effects on satiation, hunger, food reward and glucose control.

CagriSema is not one hybrid peptide. It contains two separate active molecules within one development programme and proposed pharmaceutical presentation.

Each component therefore requires its own identity, assay and impurity controls.

A commercial blend cannot be authenticated through a single chromatographic purity value.

The trial included 95 exposed participants with overweight or obesity who were otherwise considered healthy.

Multiple cagrilintide exposure groups were studied alongside semaglutide.

Cagrilintide exposure increased approximately in proportion to the administered amount and did not materially alter semaglutide exposure or elimination.

The reported cagrilintide half-life ranged from 159 to 195 hours.

Gastrointestinal disorders accounted for 37% of all recorded adverse events, although most events were mild to moderate.

A substantial mean weight reduction was observed during the short trial, providing support for larger studies.

REDEFINE 1 was a 68-week, randomised, double-blind, placebo-controlled and active-controlled phase-three trial.

It enrolled 3,417 adults with obesity or overweight and at least one weight-related complication, without diabetes.

Under the treatment-policy estimand, which includes the effects of discontinuation and treatment changes, mean weight reduction was 20.4% with CagriSema and 3.0% with placebo.

Under the trial-product estimand, mean reduction was 22.7% with CagriSema, 16.1% with semaglutide, 11.8% with cagrilintide and 2.3% with placebo.

Under the treatment-policy analysis, 53.6% of CagriSema participants reached at least 20% weight reduction.

Approximately 34.7% reached at least 25%, while 19.3% reached at least 30%.

These percentages were estimated population outcomes rather than promises for an individual.

Adverse Events

Any adverse event was reported by 92.3% of CagriSema participants and 82.3% of placebo participants.

Gastrointestinal events occurred in 79.6% of the CagriSema group, 73.8% with semaglutide, 54.0% with cagrilintide and 39.9% with placebo.

Permanent discontinuation because of any adverse event occurred in 5.9% of CagriSema participants.

Gastrointestinal events caused permanent discontinuation in 3.6% of the CagriSema group.

Gallbladder-related disorders, fatigue, dizziness, alopecia and injection-site reactions occurred more frequently with CagriSema than with placebo.

Four pancreatitis cases occurred in the CagriSema group and one in the semaglutide group.

REDEFINE 2 enrolled 1,206 adults with overweight or obesity and type 2 diabetes.

Participants received CagriSema or placebo alongside lifestyle intervention.

Under the treatment-policy estimand, mean weight reduction at 68 weeks was 13.7% with CagriSema and 3.4% with placebo.

Under the trial-product estimand, the corresponding results were 15.7% and 3.1%.

A glycated-haemoglobin level of 6.5% or below was achieved by 73.5% of the CagriSema group and 15.9% of the placebo group.

Gastrointestinal adverse events affected 72.5% of CagriSema participants and 34.4% of placebo participants.

Permanent discontinuation because of an adverse event occurred in 8.4% of CagriSema participants and 3.0% of placebo participants.

Three pancreatitis events occurred in the combination group.

The trial did not compare CagriSema directly with cagrilintide or semaglutide monotherapy.

Novo Nordisk announced headline REIMAGINE 2 results in February 2026.

The 68-week study enrolled 2,728 adults whose diabetes was inadequately controlled by metformin with or without an SGLT2 inhibitor.

Under the efficacy estimand, CagriSema produced a 1.91-percentage-point reduction in glycated haemoglobin, compared with 1.76 points for semaglutide.

Mean weight reduction was 14.2% with CagriSema and 10.2% with semaglutide.

Novo Nordisk described the common adverse events as gastrointestinal and predominantly mild to moderate.

These were company-reported headline data at the date reviewed. Detailed peer-reviewed results were expected to be presented during 2026.

RENEW Monotherapy Programme

Cagrilintide entered the phase-three RENEW programme after its independent REDEFINE 1 results.

RENEW 1 is evaluating cagrilintide in adults with overweight or obesity without diabetes.

RENEW 2 is evaluating cagrilintide in people with overweight or obesity and type 2 diabetes.

These trials are intended to provide more direct evidence about cagrilintide without semaglutide.

CagriSema Regulatory Submission

Novo Nordisk reported submitting CagriSema to the US FDA for weight management in December 2025.

A submitted application remains subject to scientific, manufacturing, clinical and labelling review.

No FDA approval for CagriSema was identified as of 22 July 2026.

Cardiovascular Outcomes

REDEFINE 3 is an event-driven cardiovascular-outcomes trial involving approximately 7,000 adults with established cardiovascular disease and overweight or obesity.

The study is intended to assess cardiovascular safety and whether CagriSema affects major cardiovascular events.

Weight reduction and lower risk-factor measurements cannot substitute for completed cardiovascular-outcome evidence.

Paediatric Research

MHRA and EMA paediatric-development records exist for cagrilintide and its combination with semaglutide.

Paediatric investigation planning is a development requirement and does not establish that the medicine is suitable or authorised for children.

• Cagrilintide remains an investigational medicine.
• No current UK marketing authorisation was identified.
• No FDA approval was identified as of the review date.
• The independent RENEW phase-three programme remains in progress.
• Long-term cardiovascular-outcome evidence is not yet complete.
• Clinical trials were funded by the manufacturer.
• Several publications include company-employed investigators.
• Trial participants were selected using eligibility criteria.
• Results may not generalise to every medical condition.
• Average results do not predict individual response.
• Some participants did not reach the highest planned exposure.
• Flexible modification complicates simple dose comparisons.
• Trial-product and treatment-policy estimands answer different questions.
• The larger 22.7% result assumes continued treatment adherence.
• The treatment-policy REDEFINE 1 estimate was lower at 20.4%.
• CagriSema data cannot define cagrilintide’s independent effects fully.
• Semaglutide contributes to efficacy and adverse events.
• Type 2 diabetes populations show different responses.
• Gastrointestinal events are common.
• Long-term nutritional consequences require further study.
• Lean soft-tissue loss can accompany substantial weight loss.
• Weight regain after discontinuation is not fully characterised.
• Rare pancreatic events require larger cumulative exposure.
• Gallbladder risk may be influenced by rapid weight reduction.
• Long-term pregnancy and reproductive safety is not established.
• Paediatric efficacy and safety remain under investigation.
• People with severe gastrointestinal disease may be underrepresented.
• Grey-market products may not contain cagrilintide.
• An unlipidated backbone is not authentic cagrilintide.
• Incorrect lipid attachment can alter pharmacokinetics.
• Incorrect disulphide pairing can alter receptor activity.
• A standard HPLC result cannot prove lipidated-peptide identity.
• Research products may lack endotoxin and sterile controls.

Most recorded adverse events have involved the gastrointestinal system.

Injection-site reactions, fatigue, dizziness and allergic-type events have also been reported.

The combination with semaglutide produces more gastrointestinal events than cagrilintide monotherapy.

Serious adverse events occurred in all REDEFINE 1 groups and were not confined to one organ system.

A clinical trial is not necessarily large enough to identify very rare adverse effects or risks emerging after several years.

No authorised prescribing information currently defines contraindications, warning language, interactions or monitoring requirements specifically for UK cagrilintide use.

Cagrilintide Monotherapy

In the REDEFINE 1 cagrilintide group, approximately 54% reported a gastrointestinal adverse event.

Nausea affected approximately 23.8%, constipation 20.5%, diarrhoea 15.2% and vomiting 7.0%.

These events were more frequent than with placebo.

CagriSema

In REDEFINE 1, approximately 79.6% of CagriSema participants reported a gastrointestinal event.

Nausea affected approximately 55.0%, constipation 30.7%, vomiting 26.1% and diarrhoea 24.5%.

Nausea, vomiting and diarrhoea were most prevalent during escalation and generally became less common later.

Constipation remained more persistent across the treatment period.

Clinical Significance

Repeated vomiting or diarrhoea can cause dehydration, electrolyte disturbance and kidney injury.

Persistent appetite suppression can also reduce protein, vitamin, mineral and fluid intake.

Delayed gastric movement may be relevant before anaesthesia or procedures requiring fasting, although specific cagrilintide guidance has not yet been authorised.

Gallbladder Disorders

Gallbladder-related disorders occurred in 4.1% of the CagriSema group, 3.0% with semaglutide, 2.3% with cagrilintide and 1.0% with placebo in REDEFINE 1.

Rapid or substantial weight reduction independently increases the likelihood of gallstones.

This makes it difficult to assign every event solely to direct receptor pharmacology.

Pancreatitis

Pancreatitis was reported in four CagriSema participants and one semaglutide participant in REDEFINE 1.

Three events were reported with CagriSema in REDEFINE 2.

These small numbers cannot define comparative risk reliably.

Severe persistent abdominal pain, particularly with vomiting or pain radiating to the back, requires urgent medical assessment.

Amylin analogues can suppress post-meal glucagon and slow nutrient delivery from the stomach.

These effects may alter the timing of glucose appearance after food.

Cagrilintide alone is not expected to stimulate insulin secretion directly in the same way as a GLP-1 receptor agonist.

CagriSema includes semaglutide, which enhances glucose-dependent insulin secretion.

Hypoglycaemia risk can increase when appetite and food intake fall in someone continuing insulin or a medicine that stimulates insulin independently of glucose.

The low overall incidence recorded in controlled trials does not establish safety for unmonitored combinations or people with unpredictable food intake.

A supportive REDEFINE 1 body-composition analysis assessed a subgroup using dual-energy X-ray absorptiometry.

Novo Nordisk reported that approximately two-thirds of total CagriSema weight loss represented fat mass and one-third represented lean soft-tissue mass.

Lean soft tissue is not identical to skeletal muscle because it also includes water, organs and other non-fat tissues.

The analysis does not establish that cagrilintide preserves muscle more effectively than every other weight-management intervention.

Adequate protein intake, resistance exercise, treatment of deficiencies and assessment of frailty remain important during substantial weight loss.

Excessive appetite suppression can make nutritional targets difficult to achieve.

Weight-management trials exclude people who are pregnant, breastfeeding or planning pregnancy during the study.

Intentional pharmacological weight loss is generally inappropriate during pregnancy.

Cagrilintide’s prolonged half-life means exposure would not end immediately after discontinuation.

Adequate human evidence concerning embryo-fetal development, breastfeeding transfer and long-term child outcomes has not been established.

Improved ovulation can occur after substantial weight reduction in some people, which may increase the possibility of pregnancy even without a direct fertility-drug effect.

Weight Maintenance

It is not yet known how much weight is regained after long-term cagrilintide discontinuation.

Experience with other appetite-regulating medicines suggests that biological pressures favouring weight regain can return when treatment ends.

Cardiovascular Outcomes

Lower blood pressure, waist circumference and inflammatory markers are encouraging risk-factor changes.

They do not prove fewer heart attacks, strokes or cardiovascular deaths.

REDEFINE 3 is intended to answer this outcome question for CagriSema.

Nutritional and Functional Outcomes

Long-term monitoring must consider muscle function, bone health, micronutrient intake and quality of life rather than body weight alone.

Rare Adverse Effects

Uncommon immune, pancreatic, gallbladder, psychiatric or neoplastic signals may require exposure across much larger populations.

• Incorrect peptide entirely
• Unlipidated 37-residue backbone
• Incomplete amino-acid sequence
• Incorrect N14E substitution
• Incorrect V17R substitution
• Missing proline substitutions
• Incorrect C-terminal residue
• Missing C-terminal amidation
• Reduced cysteine residues
• Incorrect Cys2-to-Cys7 disulphide pairing
• Fatty side chain attached at the wrong position
• Incomplete gamma-glutamyl linker
• Incorrect fatty-acid chain length
• Free unbound lipid impurity
• Deletion-sequence impurities
• Epimerised amino acids
• Oxidised methionine-free but other oxidative products
• Deamidation of asparagine or glutamine residues
• Peptide aggregates
• Lipid-related micelles or particles
• Incorrect net peptide quantity
• Residual synthesis reagents
• Residual organic solvents
• Residual trifluoroacetate
• Unverified endotoxin control
• Unverified sterile quality
• Particulate contamination
• Degradation during transport
• Incorrect CagriSema component ratio
• Certificate unrelated to the supplied batch

What Meaningful Cagrilintide Documentation Should Include

• Complete cagrilintide identity
• Full 37-residue sequence
• Confirmation of all six substitutions
• Observed intact molecular mass
• Peptide-map sequence coverage
• Tandem-MS fragment evidence
• Confirmation of Lys1 lipidation
• Gamma-glutamyl-linker identity
• Fatty-acid-chain identity
• Free lipid impurity result
• Cys2-to-Cys7 disulphide map
• Reduced-thiol result
• C-terminal amidation result
• Net cagrilintide assay
• Chromatographic purity
• Deletion-sequence profile
• Deamidation profile
• Epimerisation assessment where relevant
• Aggregate and particle analysis
• Albumin-binding characterisation where relevant
• Amylin-receptor potency
• Calcitonin-receptor potency
• Residual-solvent results
• Residual synthesis-reagent results
• Counterion result
• Water-content result
• Bacterial-endotoxin result
• Sterility result for finished injectable medicine
• Visible and subvisible particle results
• Batch-specific stability evidence
• Testing-laboratory identity
• Analytical methods and acceptance criteria
• A statement identifying tests not performed

Why “99% HPLC” Is Not Enough

HPLC area purity does not prove that the main peak contains the complete lipidated cagrilintide molecule.

An unlipidated precursor, incorrectly attached lipid, unamidated variant or disulphide error may remain chemically similar.

Conventional reverse-phase analysis may also underrepresent aggregates, free lipid, particles, endotoxins and microbiological contamination.

A certificate for raw peptide does not establish the quality of the finished vial or combination product.

MHRA Development Records

The MHRA records a paediatric investigation plan for cagrilintide as an obesity-treatment candidate.

Separate plans exist for cagrilintide with semaglutide in obesity and type 2 diabetes.

The records identify no currently available invented UK medicine name.

Paediatric planning is part of medicine development and should not be confused with a positive benefit-risk decision.

Medicinal-Product Classification

A product presented as reducing obesity, suppressing appetite, treating diabetes or modifying body weight through receptor pharmacology is strongly medicinal in character.

MHRA classification considers intended use, claims, pharmacological action, labels, imagery, testimonials, websites and customer instructions.

“Research Use Only” Wording

A research disclaimer does not determine legal status where surrounding material encourages personal administration or describes treatment outcomes.

Advertising Restrictions

Regulation 279 of the Human Medicines Regulations restricts advertising a medicinal product unless the required authorisation, registration or certificate is in force.

This section provides general regulatory education and does not constitute legal advice.

WADA section S0 prohibits pharmacologically active substances that are not addressed elsewhere in the list and do not have current approval by a governmental regulatory health authority for human therapeutic use.

Cagrilintide remained investigational and lacked identified regulatory approval on the review date.

It may therefore fall within S0 as a non-approved substance. This is an application of the published rule rather than a cagrilintide-specific WADA entry.

A combination product can also contain separately prohibited or undeclared ingredients.

Athletes should obtain a current product-specific ruling through UK Anti-Doping, Global DRO or their international federation.

• Is the substance cagrilintide or CagriSema?
• Is it distinguished from semaglutide?
• Is it distinguished from pramlintide?
• Is the complete 37-residue sequence stated?
• Are all six substitutions confirmed?
• Is the Lys1 lipid attachment verified?
• Is the gamma-glutamyl linker identified?
• Is the fatty-acid chain confirmed?
• Is the Cys2-to-Cys7 disulphide bond mapped?
• Is C-terminal amidation confirmed?
• Was intact mass measured?
• Was tandem-MS sequence coverage provided?
• Were deletion sequences assessed?
• Were free lipid and partial conjugates assessed?
• Were aggregates and particles measured?
• Was receptor potency tested?
• Was net peptide quantity measured?
• Was bacterial endotoxin tested?
• Was finished-product sterility demonstrated?
• Does the certificate match the supplied batch?
• Was the study monotherapy or combination therapy?
• Did participants have type 2 diabetes?
• Was the result treatment-policy or trial-product estimand?
• Were discontinuations included?
• How many participants reached the planned exposure?
• Was weight regain after stopping assessed?
• Were cardiovascular events measured?
• Were gallbladder and pancreatic events reported?
• Was body composition measured?
• Is a CagriSema result being attributed to cagrilintide alone?
• Is a regulatory submission being presented as approval?
• Is an MHRA paediatric plan being presented as authorisation?
• Is the source selling the product it describes?

The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.

Medical Director and Clinical Reviewer

Dr Laura Geige

Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.

Read professional profile

Medical and Nutritional Sciences Reviewer

Dr Rimas Geiga

Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.

Read professional profile

Medical and Healthcare Reviewer

Dr Snieguole Geige

Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.

Read professional profile

Dermatology Reviewer

Dr Giedre Narkiene

Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.

Read professional profile

Medical and Gerontology Reviewer

Dr Veronika Matutyte

Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.

Read professional profile

Cosmetology and Skin Health Contributor

Livija Samušienė

Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.

Read professional profile